Table 3.
Study A | Study B | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
Taking ARVs now | CD4 (cells/mm3) – DHHS category | N in group | % in group | Symptom Frequency Mean (0–64) | SD | Symptom Intensity Mean (0–192) | SD | N in group | % in group | Symptom Frequency Mean (0–64) | SD | Symptom Intensity Mean (0–192) | SD |
No | 0–200 | 38 | 21.7% | 21.2 | 20.1 | 46.2 | 53.2 | 29 | 22.0% | 18.7 | 17.5 | 40.0 | 41.1 |
201–350 | 22 | 12.6% | 23.8 | 18.2 | 37.7 | 40.7 | 31 | 23.4% | 20.4 | 20.2 | 39.4 | 33.2 | |
351 and higher | 115 | 65.7% | 19.7 | 19.2 | 37.0 | 39.2 | 72 | 54.5% | 19.3 | 16.9 | 37.0 | 30.7 | |
Total No | 175 | 20.5 | 19.2 | 38.5 | 39.8 | 132 | 19.4 | 17.7 | 38.2 | 33.5 | |||
| |||||||||||||
Yes | 0–200 | 182 | 28.2% | 19.7 | 17.0 | 31.0 | 29.8 | 89 | 25.7% | 21.9 | 17.8 | 44.4 | 37.5 |
201–350 | 138 | 21.3% | 16.4 | 15.0 | 32.5 | 33.9 | 70 | 20.2% | 22.2 | 20.6 | 43.5 | 39.7 | |
351 and higher | 325 | 50.3% | 17.2 | 16.0 | 30.1 | 30.0 | 186 | 19.7% | 20.8 | 18.2 | 40.6 | 35.4 | |
Total Yes | 645 | 17.8 | 16.1 | 32.2 | 31.4 | 345 | 21.4 | 18.6 | 42.2 | 36.8 | |||
| |||||||||||||
Combined | 0–200 | 220 | 26.8% | 19.9 | 17.5 | 33.48 | 34.9 | 118 | 24.7% | 21.0 | 17.7 | 42.9 | 38.1 |
201–350 | 160 | 19.5% | 17.5 | 15.6 | 33.22 | 34.9 | 101 | 21.1% | 21.7 | 20.3 | 42.3 | 37.5 | |
351 and higher | 440 | 53.7% | 17.9 | 16.9 | 31.8 | 32.3 | 258 | 54.1% | 20.4 | 17.8 | 39.8 | 34.4 | |
Total Combined | 820 | 18.3 | 16.8 | 33.7 | 33.8 | 477 | 20.9 | 18.3 | 41.1 | 36.0 |